Global Gene Editing Partnering Terms and Agreements 2010 to 2022

$3,995.00

The Global Gene Editing Partnering Terms and Agreements 2010-2022 report provides comprehensive understanding and unprecedented access to the gene editing partnering deals and agreements entered into by the worlds leading healthcare companies.

Publication date
September 2022
Number of pages
300+
Product type
Research report
Available formats
PDF document
Report edition
1
SKU
CP2150

The Global Gene Editing Partnering Terms and Agreements 2010-2022 report provides an understanding and access to the gene editing partnering deals and agreements entered into by the worlds leading healthcare companies.

 

  • Trends in gene editng partnering deals
  • Disclosed headlines, upfronts, milestones and royalties by stage of development
  • Gene editing partnering contract documents
  • Top gene editing deals by value

 

The Global Gene Editing Partnering Terms and Agreements 2010-2022 report provides an understanding and access to the gene editing partnering deals and agreements entered into by the worlds leading healthcare companies.

 

The report provides a detailed understanding and analysis of how and why companies enter gene editing partnering deals. The majority of deals are early development stage whereby the licensee obtains a right or an option right to license the licensors gene editing technology or product candidates. These deals tend to be multicomponent, starting with collaborative R&D, and commercialization of outcomes. 

 

This report provides details of the latest gene editing agreements announced in the healthcare sectors.  

 

Understanding the flexibility of a prospective partner’s negotiated deals terms provides critical insight into the negotiation process in terms of what you can expect to achieve during the negotiation of terms. Whilst many smaller companies will be seeking details of the payments clauses, the devil is in the detail in terms of how payments are triggered – contract documents provide this insight where press releases and databases do not.

 

This report contains a comprehensive listing of all gene editing partnering deals announced since 2010 including financial terms where available including over 400 links to online deal records of actual gene therapy partnering deals as disclosed by the deal parties. In addition, where available, records include contract documents as submitted to the Securities Exchange Commission by companies and their partners.

 

Contract documents provide the answers to numerous questions about a prospective partner’s flexibility on a wide range of important issues, many of which will have a significant impact on each party’s ability to derive value from the deal.

 

For example, analyzing actual company deals and agreements allows assessment of the following:

  • What is actually granted by the agreement to the partner company?
  • What exclusivity is granted?
  • What are the precise rights granted or optioned?
  • What is the payment structure for the deal?
  • How are sales and payments audited?
  • What is the deal term?
  • How are the key terms of the agreement defined?
  • How are IPRs handled and owned?
  • Who is responsible for commercialization?
  • Who is responsible for development, supply, and manufacture?
  • How is confidentiality and publication managed?
  • How are disputes to be resolved?
  • Under what conditions can the deal be terminated?
  • What happens when there is a change of ownership?
  • What sublicensing and subcontracting provisions have been agreed?
  • Which boilerplate clauses does the company insist upon?
  • Which boilerplate clauses appear to differ from partner to partner or deal type to deal type?
  • Which jurisdiction does the company insist upon for agreement law?

 

The initial chapters of this report provide an orientation of gene editing dealmaking and business activities. Chapter 1 provides an introduction to the report, whilst chapter 2 provides an overview of the trends in gene editing dealmaking since 2010, including details of average headline, upfront, milestone and royalty terms.

 

Chapter 3 provides a review of the leading gene editing deals since 2010. Deals are listed by headline value, signed by big pharma, most active gene editing dealmaking companies. Where the deal has an agreement contract published at the SEC a link provides online access to the contract.

 

Chapter 4 provides a comprehensive listing of the top 25 most active companies in gene editing dealmaking with a brief summary followed by a comprehensive listing of gene editing deals, as well as contract documents available in the public domain. Where available, each deal title links via Weblink to an online version of the actual contract document, providing easy access to each contract document on demand.

 

Chapter 5 provides a comprehensive and detailed review of gene editing partnering deals signed and announced since Jan 2010, where a contract document is available in the public domain. Each deal title links via Weblink to an online version of the deal record and where available, the contract document, providing easy access to each contract document on demand.

 

Chapter 6 provides a comprehensive and detailed review of gene editing partnering deals signed and announced since Jan 2010. The chapter is organized by specific gene editing technology type in focus. Each deal title links via Weblink to an online version of the deal record and where available, the contract document, providing easy access to each contract document on demand.

 

In addition, a comprehensive appendix is provided organized by gene editing partnering company A-Z, deal type definitions and gene editing partnering agreements example. Each deal title links via Weblink to an online version of the deal record and where available, the contract document, providing easy access to each contract document on demand.

 

The report also includes numerous tables and figures that illustrate the trends and activities in gene editing partnering and dealmaking since 2010.

 

In conclusion, this report provides everything a prospective dealmaker needs to know about partnering in the research, development and commercialization of gene editing technologies and products.

 

Report scope

 

Global Gene Editing Partnering Terms and Agreements is intended to provide the reader with an in-depth understanding and access to gene editing trends and structure of deals entered into by leading companies worldwide.

 

Global Gene Editing Partnering Terms and Agreements includes:

 

  • Trends in gene editing dealmaking in the biopharma industry since 2010
  • Access to headline, upfront, milestone and royalty data
  • Access to over 400 gene therapy deals
  • The leading gene editing deals by value since 2010
  • Most active gene editing dealmakers since 2010
  • The leading gene editing partnering resources

 

 In Global Gene Editing Partnering Terms and Agreements, the available contracts are listed by:

 

  • Company A-Z
  • Headline value
  • Stage of development at signing
  • Deal component type
  • Specific therapy and technology target

 

Each deal title links via Weblink to an online version of the deal record and where available, the contract document, providing easy access to each contract document on demand. 

Global Gene Editing Partnering Terms and Agreements provides the reader with the following key benefits:

 

  • In-depth understanding of Gene Editing deal trends since 2010
  • Access to headline, upfront, milestone and royalty data
  • Comprehensive access to over 400 actual gene editing deals entered into by the world’s biopharma companies, together with real world clause examples
  • Full listing of gene editing deals by company A-Z, deal value, phase of development, deal type, and therapy focus
  • Identify leading gene editing deals by value since 2010
  • Identify the most active gene editing dealmakers since 2010
  • Detailed access to actual gene editing contracts enter into by the leading bigpharma
  • Insight into the terms included in gene editing agreement, together with real world clause examples
  • Understand the key deal terms companies have agreed in previous deals     
  • Undertake due diligence to assess suitability of your proposed deal terms for partner companies

Executive Summary

 

Chapter 1 – Introduction

 

Chapter 2 – Trends in Gene Editing dealmaking

 

2.1. Introduction
2.2. Gene editing partnering over the years
2.3. Most active Gene Editing dealmakers
2.4. Gene Editing partnering by deal type
2.5. Gene Editing partnering by therapy area
2.6. Deal terms for Gene Editing partnering
2.6.1 Gene Editing partnering headline values
2.6.2 Gene Editing deal upfront payments
2.6.3 Gene Editing deal milestone payments
2.6.4 Gene Editing royalty rates

 

Chapter 3 – Leading Gene Editing deals

 

3.1. Introduction
3.2. Top Gene Editing deals by value

 

Chapter 4 – Most active Gene Editing dealmakers

 

4.1. Introduction
4.2. Most active Gene Editing dealmakers
4.3. Most active Gene Editing partnering company profiles

 

Chapter 5 – Gene Editing contracts dealmaking directory

 

5.1. Introduction
5.2. Gene Editing contracts dealmaking directory

 

Chapter 6 – Gene Editing dealmaking by technology type

 

Appendices

 

Appendix 1 – Gene Editing deals by company A-Z

Appendix 2 – Gene Editing deals by stage of development

Appendix 3 – Gene Editing deals by deal type

Appendix 4 – Gene Editing deals by therapy area

Appendix 5 – Deal type definitions

Appendix 6 – Further reading

 

About Wildwood Ventures

 

Current Partnering
Current Agreements
Recent report titles from Current Partnering

 

Table of figures

 

Figure 1: Gene Editing partnering since 2010
Figure 2: Active Gene Editing dealmaking activity since 2010
Figure 3: Gene Editing partnering by deal type since 2010
Figure 4: Gene Editing partnering by disease type since 2010
Figure 5: Gene Editing deals with a headline value
Figure 6: Gene Editing deals with an upfront value
Figure 7: Gene Editing deals with a milestone value
Figure 8: Gene Editing deals with a royalty rate value
Figure 9: Top Gene Editing deals by value since 2010
Figure 10: Most active Gene Editing dealmakers since 2010

Pricing options

  • $3,995: single-user
  • $5,745: multi-user
  • $10,995: single site license
  • $17,995: global site license

 

A full explanation of license type definitions can be found here.

 

Our guarantee

 

Price promise

We guarantee our prices are competitive. If you find the same report advertised at a lower price within 7 days of purchase, we will refund the difference.

 

Delivery Deadline

We guarantee that the report will be sent within the specified delivery times. In the unlikely case of a delay we may offer a partial refund as compensation. (Terms may apply)

 

Latest report

If an update is published within 30 days of your purchase, you will receive it absolutely free of charge.

 

Serious Security

We take your data and security seriously. See our privacy policy for details of how we manage your data.

All card payments are processed by SagePay.

 

Sales Support

If you have any questions about your report or are unhappy with the quality, we will do our best to resolve your query. Contact us direct.

 

Total Trust

Current Partnering is part of Wildwood Ventures Ltd., based in York, United Kingdom. We have been trading successfully online since 2009 and work with some of the most famous brands in the business. We carefully select our partners to ensure that the publications meet expectations of demanding customers.

2seventy bio, 221b Foundation, Abbvie, Abcam, AccuRef Diagnostics, Adaptimmune, Adarza BioSystems, Advanced Biological Innovation and Manufacturing, Adverum Biotechnologies, Aelian Biotechnology, Agribody Technologies, Albany Molecular Research, ALBOT Technologies, Alcyone Lifesciences, Aldevron, Allele Biotechnology and Pharmaceuticals, Allergan, Allogene Therapeutics, American Skin Association, Amfora, AmplyCell, Amsterdam Molecular Therapeutics, Amyris, Anagenesis Biotechnologies, Analytical Biological Services, Ancilia Biosciences, Ankarys Therapeutics, APG Bio, Applied StemCell, Arbor Biotechnologies, Arbutus, Artisan Bio, Asklepios Biopharmaceutical, Astellas Pharma, Asterand Bioscience, AstraZeneca, ATUM, Avectas, Avellino Labs, Avita Therapeutics, Avvinity Therapeutics, Axcelead Drug Discovery Partners, Axxam, B-MoGen Biotechnologies, Bachmann-Strauss Dystonia & Parkinson Foundation, BASF, Batavia Biosciences, Baxalta, Baxter International, Bayer, Bayer CropScience, Beam Therapeutics, Benson Hill Biosystems, Berkeley Lights, Beth Israel Deaconess Medical Center, Bill and Melinda Gates Foundation, Binx Health, Bio-Techne, Biogen, Bioheuris, Biomedical Advanced Research and Development Authority, Bioneer, Bioverativ, Bird Foundation, Blood Systems Research Institute, Bluebird Bio, BlueRock Therapeutics, Bone Therapeutics, Boundary Capital, Brigham and Women's Hospital, Bristol-Myers Squibb, Broad Institute, Brooklyn ImmunoTherapeutics, C4X Discovery, Cabaletta Bio, California Institute for Regenerative Medicine, California Institute of Technology, Calyxt, CANbridge Pharmaceuticals, Cancer Research UK, Canopy Biosciences, Capsida Biotherapeutics, CARB-X, Caribou Biosciences, Casebia Therapeutics, Case Western Reserve University, CasZyme, Catalent, Catamaran Bio, Celgene, Cellecta, Cellectis, Cellectis Bioresearch, Celltech, Cellular Dynamics International, Cellular Engineering Technologies, Centauri Therapeutics, Center for Human Genetics and Laboratory Medicine, Cepheid, CGA 369, Charles River Laboratories, Chatham Therapeutics, China Agricultural University, City of Hope, Clontech Laboratories, COBO Technologies, Cocrystal Pharma, Codiak BioSciences, Cofactor Genomics, Columbia University, Columbia University Medical Center, CombinatoRx, Corteva Agriscience, Cosmo Bio, CRISPR Therapeutics, Cumming, Cyrus Biotechnology, Cystic Fibrosis Foundation, CytoLynx Therapeutics, CYTOVIA Therapeutics, Czech Center for Phenogenomics, Daiichi Sankyo, Dana-Farber Cancer Institute, Dartmouth-Hitchcock Medical Center, Defense Threat Reduction Agency, DefiniGEN, Desktop Genetics, Dow AgroSciences, Duke University, DuPont, DuPont Pioneer, EdiGene, Editas Medicine, eGenesis, Eisai, Eligo Bioscience, Eli Lilly, EMBRAPA, Emendo Biotherapeutics, Emory University, EpiBiome, Erasmus University Medical Center, ERS Genomics, Eurofins Genomics, Evogene, Evolva, Evotec, Excision BioTherapeutics, Execute Technologies, Exonics Therapeutics, Expression Analysis, Factor Bioscience, FASMAC, Fox Chase Cancer Center, Frederick National Laboratory For Cancer Research, Fresenius Kabi Pharmaceuticals, Friedreichs Ataxia Research Alliance, Fujifilm, Fujifilm Diosynth Biotechnologies, Fulcrum Therapeutics, FuturaGene, G+FLAS Life Sciences, Gamida Cell, GDM Seeds, GE Healthcare, Geisel School of Medicine at Dartmouth, GEMoaB, GenAhead Bio, GenEdit, Genentech, GeneThera, Genetic Information Research Institute, Genevant Sciences, Genome Compiler, Genomic Vision, genOway, GenScript Biotech, Gensus, Genus, GenVec, Gilead Sciences, Ginkgo BioWorks, GlaxoSmithKline, Goethe University Frankfurt, Great Ormond Street Hospital (GOSH), Greenlight Biosciences, GSK Consumer Healthcare, H3 Biomedicine, Haplogen, Harvard Medical School, Harvard Stem Cell Institute, Harvard University, HebeCell, Helen F Graham Cancer Center, Helmholtz Zentrum Munchen, Hillstream BioPharma, Homology Medicines, Horizon CombinatoRx, Horizon Discovery, Horizon Pharma plc, Humanigen, Hunterian Medicine, IBM Watson Health, IDbyDNA, IDEAYA Biosciences, iECURE, Illumina, ImmunoChina Pharmaceuticals, Imperial College London, Implant Therapeutics, InnoBation, Innovative Genomics Initiative (IGI), Inscripta, Institute of Crop Sciences, Integrated DNA Technologies, Intellia Therapeutics, Iovance Biotherapeutics, Iowa State University, Israeli National Authority for Technological Innovation, Jackson Laboratory, Janssen Biotech, Janssen Pharmaceuticals, Japan SLC, Johns Hopkins University, Juno Therapeutics, Keck Graduate Institute of Applied Life Sciences, Kiromic Biopharma, Kite Pharma, Knudra Transgenics, Kraig Biocraft Laboratories, KSQ Therapeutics, KWS SAAT, KY Cabinet for Economic Development, Kytopen, Kyverna Therapeutics, Leicester University, Les Laboratoires Servier, Life Edit Therapeutics, Life Technologies, Locus Biosciences, LogicBio Therapeutics, LogicInk, Lonza, Ludwig Institute for Cancer Research, Lysogene, Mammoth Biosciences, Marina Biotech, Massachusetts Eye and Ear Infirmary, Massachusetts General Hospital, Massachusetts Institute of Technology, MassBiologics, MaSTherCell, Max-Delbruck Center for Molecular Medicine, Maxcyte, Mayo Clinic, MD Anderson Cancer Center, Medical College of Wisconsin, MediGene, Meiogenix, Mendel Biotechnology, Merck and Co, Merck KGaA, Metagenomi, MilliporeSigma, Modalis Therapeutics, Moderna Therapeutics, Molecular Templates, Monsanto, Muscular Dystrophy Association, Mustang Bio, Nanjing Darwingenetech, National Cancer Institute, National Heart, Lung and Blood Institute, National Human Genome Research Institute, National Institute of Allergy and Infectious Diseases, National Institute of Neurological Disorders and Stroke, National Institute on Aging, National Institutes of Health, National Kidney Foundation, National Organization for Rare Disorders, National Science Foundation, Naval Medical Research Center, Ncardia, Neon Therapeutics, Netherlands Cancer Institute, New England Biolabs, New York University School of Medicine, Nippon Gene, Nkarta Therapeutics, NMI Natural and Medical Sciences Institute, Nomad Bioscience, Novartis, Novellus Biopharma, NovellusDx, Novellus Therapeutics, Novome Biotechnologies, Novo Nordisk, Nrgene, Nucelis, Nuvisan Pharma Services, Obsidian Therapeutics, ONK Therapeutics, Oregon Health Sciences University, Origin Agritech, Otsuka, Oxford Genetics, Oxford Nanopore Technologies, Oxgene, Pairwise Plants, Parent Project Muscular Dystrophy, Paul Ehrlich Institute, Pfizer, Pioneer Hi-Bred, Plant Bioscience Limited, Plasticell, Pluristem Therapeutics, Poseida Therapeutics, Precision BioSciences, Prime Medicine, ProBioGen, Promega, Pro Pharmaceuticals, Protein Sciences, Proventus Bio, Qihan Biotech, Recombinetics, Regeneron Pharmaceuticals, ReGenX Biosciences, Repare Therapeutics, Roche, Roche Diagnostics, Roivant Sciences, Rokline Health Concepts, Rosalind Franklin University of Medical Sciences, Rosetta Biosciences, Rutgers University, S&W Seed Company, Sage Labs, Saint Louis University, Sana Biotechnology, Sangamo Therapeutics, Sanofi, San Raffaele Scientific Institute, Sarepta Therapeutics, Sciex, SCM Pharma, Scribe Therapeutics, Seattle Childrens Research Institute, Selecta Biosciences, Seracare Life Sciences, Setsuro Tech, Shape Therapeutics, Sherlock Biosciences, Shire Pharmaceuticals, Sigma-Aldrich, Sigma Life Science, Sirion Biotech, SiSaf, Solentim, SparingVision, Sphere Fluidics, StrideBio, Synbal, Syngenta, Syngulon, Synthego, Taconic Biosciences, Takeda Pharmaceutical, Takeda Ventures, Tango Therapeutics, Target ALS Foundation, TCR2 Therapeutics, Temple University, The Human Protein Atlas, The New York Stem Cell Foundation, Thermo Fisher Scientific, Thomas Jefferson University, Thrive Bioscience, Toolgen, Transcriptic, Transgenomic, Transposagen Biopharmaceuticals, Tropic Biosciences, Twist Bioscience, Two Blades Foundation, Ulster University, Universal Cells, University of Alabama, University of Alabama at Birmingham, University of Arkansas, University of British Columbia, University of California, Davis, University of California Berkeley, University of California Los Angeles, University of California San Francisco, University of Colorado, University of Colorado Denver, University of Edinburgh, University of Freiburg, University of Illinois, University of Iowa, University of Kansas, University of Manchester, University of Massachusetts, University of Massachusetts Medical School, University of Michigan Medical School, University of Minnesota, University of Nebraska, University of Oxford, University of Pennsylvania, University of Pittsburgh, University of Texas, University of Texas Southwestern Medical Center, University of Tokyo, University of Utah, University of Washington, University of Wisconsin, University of Wisconsin-Madison, US Department of Agriculture, Vectalys, Ventana Medical Systems, Vertex Pharmaceuticals, VIB, Vir Biotechnology, Virginia Commonwealth University, Vivlion, Vor Biopharma, Voyager Therapeutics, Wageningen University, Wake Forest University, Wako Pure Chemicals Industries, Washington University in St Louis, Weill Cornell Medical College, Wellcome Trust Sanger Institute, Whitehead Institute, Wilson Wolf, Yale School of Medicine, Yale University, Yield10 Bioscience, Zalicus, ZeClinics

Current Partnering reports provide insight into the trends and terms of partnering deals in the global life sciences sector.

Current Partnering reports are updated every six months to ensure the user has access to the latest announcements and trends in the topic focus of the report.

Current Partnering analysts review the deal data to provide an overview and analysis of deal trends, including example deals and terms.

Current Partnering reports source deal data from our proprietary deals and alliances database, Current Agreements. The database is updated daily by our analysts with new deals as they are announced globally by the company’s party to the deal. In addition, deal records are updated with new data as it becomes available.

The data in the Current Agreements deals and alliances database is obtained from secondary sources such as publicly available industry sources including press releases, company presentations, investor presentations, company SEC filings, other company filings, company websites, conference presentations. Sources are identified to allow for user verification.

Current Partnering provides comprehensive coverage of the following partnering or deal types:
• Asset purchase
• Assignment
• Co-development
• Co-market
• Co-promotion
• Collaborative R&D
• Contract service
• CRADA
• Cross-licensing
• Development
• Distribution
• Equity purchase
• Evaluation
• Grant
• Joint venture
• Licensing
• Loan
• Manufacturing
• Marketing
• Option
• Promotion
• Research
• Royalty financing
• Settlement
• Spin out
• Sub license
• Supply
• Termination
• Warrant

Every deal record is fully categorized and includes the following data, where available:
• Industry sector
• Therapy areas
• Technology type
• Deal components
• Financial terms
• Stage of development
• Exclusivity
• Asset type
• Geographic focus
• Excluded geography
• Company press release
• SEC filing data including contract document

All financial amounts are converted to US$ using the exchange rate available on the date of deal announcement, enabling direct comparison of deal terms across international territories.

Financial data and contract documents displayed in deal records is obtained from public sources, where disclosed by the parties to the deal.